An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Study Identifier
M13-886
CT.gov Identifier
NCT02082197
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Men's Health
    • Study Drug
  • ABT-SLV176
    • Phase
    Phase 3
    Sex
    Male
    Age
    18 - 80 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Low testosterone
    Exclusion Criteria:
    * Normal testosterone levels * Elevated Prostatic Specific Antigen (PSA) * History of breast or prostate cancer

    Protocol Summary

    This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 124163
    Birmingham, Alabama, United States, 35213
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 123938
    Huntsville, Alabama, United States, 35801
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 125782
    Mesa, Arizona, United States, 85202
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 124157
    Phoenix, Arizona, United States, 85032
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 123937
    Tucson, Arizona, United States, 85712
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 123948
    Anaheim, California, United States, 92801
    Status
    Not applicable
    Showing {first} - {last} of {total} Results